Abstract: An accessory attachment system includes a baseplate that provides an attachment interface on a vehicle. The baseplate is configured to engage with an accessory to secure the accessory to the vehicle. The baseplate and the accessory are configured to electrically connect to each other through an electrical contact interface.

Abstract: A portable brace assembly for therapeutically supporting an area of a user's body. The assembly generally includes a belt configured to be positioned around the user. One or more inflatable bladders are attached to the belt. One or more additional therapeutic or support modalities configured to be combined with the belt. The additional modalities may be positioned over the inflatable bladders, so that in use the additional modalities are positioned between the inflatable bladders and the user's body. A transdermal medication delivery assembly may be configured to be combined with the first side of the belt as an additional modality.

Abstract: An accessory attachment system includes a baseplate that provides an attachment interface on a vehicle. The baseplate is configured to engage with an accessory to secure the accessory to the vehicle. The baseplate and the accessory are configured to electrically connect to each other through an electrical contact interface.

Abstract: An optical element retainer includes a ring body defined about a central axis. The ring body includes an inner diametric surface, an outer diametric surface opposed to the inner diametric surface, a first annular axial surface, and a plurality of flexures extending from a second annular axial surface opposite the first annular axial surface.

Abstract: An electronics assembly can include a circuit board comprising a stress sensitive device and a stiffening member operatively connected to the circuit board to stiffen the circuit board. The assembly can include a housing disposed around the circuit board and the stiffening member to contain circuit board and the stiffening member. The assembly can include one or more elastic and/or flexible bumpers disposed between the circuit board and the housing to provide shock absorption to the circuit board within the housing.

Abstract: A button assembly is disclosed including a plastic cover having an upper body portion and a lower flange portion, the upper body portion having a top wall and an interior cavity, wherein a port is formed in the top wall of the upper body portion and the lower flange portion is adapted and configured to be welded to a wall of a plastic housing, and an elastomeric button over-molded on the plastic cover and including an upper actuation portion and a lower body portion, wherein the upper actuation portion extends through the port formed in the top wall of the upper body portion of the cover, and the lower body portion resides in the interior cavity of the upper body portion of the cover.

Abstract: A button assembly is disclosed including a plastic cover having an upper body portion and a lower flange portion, the upper body portion having a top wall and an interior cavity, wherein a port is formed in the top wall of the upper body portion and the lower flange portion is adapted and configured to be welded to a wall of a plastic housing, and an elastomeric button over-molded on the plastic cover and including an upper actuation portion and a lower body portion, wherein the upper actuation portion extends through the port formed in the top wall of the upper body portion of the cover, and the lower body portion resides in the interior cavity of the upper body portion of the cover.

Abstract: An optical element retainer includes a ring body defined about a central axis. The ring body includes an inner diametric surface, an outer diametric surface opposed to the inner diametric surface, a first annular axial surface, and a plurality of flexures extending from a second annular axial surface opposite the first annular axial surface.

Abstract: A button assembly is disclosed including a plastic cover having an upper body portion and a lower flange portion, the upper body portion having a top wall and an interior cavity, wherein a port is formed in the top wall of the upper body portion and the lower flange portion is adapted and configured to be welded to a wall of a plastic housing, and an elastomeric button over-molded on the plastic cover and including an upper actuation portion and a lower body portion, wherein the upper actuation portion extends through the port formed in the top wall of the upper body portion of the cover, and the lower body portion resides in the interior cavity of the upper body portion of the cover.

Abstract: A tube retainer can include a body configured to abut a face of a tube, a plurality of flexure flanges extending radially outwardly from the body and configured to flex relative to the body to provide a retaining force to the body when installed in a housing assembly around the tube, and a plurality of flexure legs axially extending from the body from a tube contact side of the body. At least a portion of the plurality of legs can include an inner diameter that is less than an outer diameter of the tube to provide a centering force to the tube.

Abstract: An electronics assembly can include a circuit board comprising a stress sensitive device and a stiffening member operatively connected to the circuit board to stiffen the circuit board. The assembly can include a housing disposed around the circuit board and the stiffening member to contain circuit board and the stiffening member. The assembly can include one or more elastic and/or flexible bumpers disposed between the circuit board and the housing to provide shock absorption to the circuit board within the housing.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Abstract: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

Abstract: The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.

Abstract: Provided herein are 1-oxa-8-azaspiro[4.5]decane-8-carboxamide compounds of formula I wherein Ar1, Ar2, R1, R2, R3 and R4 are as defined herein and the pharmaceutically acceptable salts of such compounds useful in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, conditions including acute pain, chronic pain, neuropathic pain, nociceptive pain, inflammatory pain, fibromyalgia, rheumatoid arthritis, inflammatory bowel disease, lupus, diabetes, allergic asthma, vascular inflammation, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease.